155 related articles for article (PubMed ID: 20424627)
1. Anemia: To TREAT or not to TREAT--that is the question.
Wiecek A
Nat Rev Nephrol; 2010 May; 6(5):254-5. PubMed ID: 20424627
[No Abstract] [Full Text] [Related]
2. The TREAT study answers a question, not the question.
Coyne DW
Am J Kidney Dis; 2008 Sep; 52(3):626-7; author reply 627-8. PubMed ID: 18725019
[No Abstract] [Full Text] [Related]
3. Mitigating the cardiovascular risk of anemia in patients with type 2 diabetes and CKD: Does darbepoetin help? The TREAT Trial.
Hayes C; Alam A; Black-Peart J; McFarlane SI
Curr Diab Rep; 2010 Apr; 10(2):87-9. PubMed ID: 20425565
[No Abstract] [Full Text] [Related]
4. Diabetes, anemia and CKD: Why TREAT?
Singh AK
Curr Diab Rep; 2010 Aug; 10(4):291-6. PubMed ID: 20544312
[TBL] [Abstract][Full Text] [Related]
5. [The results of the TREAT study: lessons and limitations].
Del Vecchio L
G Ital Nefrol; 2010; 27(1):3. PubMed ID: 20191449
[No Abstract] [Full Text] [Related]
6. Erythropoietin in kidney disease and type 2 diabetes.
Donnelly S
N Engl J Med; 2011 Jan; 364(4):385; author reply 385-6. PubMed ID: 21268743
[No Abstract] [Full Text] [Related]
7. Erythropoietin in kidney disease and type 2 diabetes.
Schnuelle P; Benck U; Krämer BK
N Engl J Med; 2011 Jan; 364(4):384; author reply 385-6. PubMed ID: 21268746
[No Abstract] [Full Text] [Related]
8. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
Pfeffer MA; Burdmann EA; Chen CY; Cooper ME; de Zeeuw D; Eckardt KU; Feyzi JM; Ivanovich P; Kewalramani R; Levey AS; Lewis EF; McGill JB; McMurray JJ; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto R;
N Engl J Med; 2009 Nov; 361(21):2019-32. PubMed ID: 19880844
[TBL] [Abstract][Full Text] [Related]
9. Prospective trials on anemia of chronic disease: the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT).
Rao M; Pereira BJ
Kidney Int Suppl; 2003 Nov; (87):S12-9. PubMed ID: 14531768
[No Abstract] [Full Text] [Related]
10. Managing anemia in patients with chronic kidney disease or cancer: development and role of darbepoetin alfa.
Scott SD
Pharmacotherapy; 2002 Sep; 22(9 Pt 2):129S-132S. PubMed ID: 12222582
[No Abstract] [Full Text] [Related]
11. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
Wilhelm-Leen ER; Winkelmayer WC
Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietin in kidney disease and type 2 diabetes.
Locatelli F; Del Vecchio L; Casartelli D
N Engl J Med; 2011 Jan; 364(4):384; author reply 385-6. PubMed ID: 21268745
[No Abstract] [Full Text] [Related]
13. Erythropoietin in kidney disease and type 2 diabetes.
Thum T; Kalantar-Zadeh K; Anker SD
N Engl J Med; 2011 Jan; 364(4):384-5; author reply 385-6. PubMed ID: 21268744
[No Abstract] [Full Text] [Related]
14. No TREATment with darbepoetin dosed to hemoglobin 13 grams per deciliter in type 2 diabetes with pre-dialysis chronic kidney disease--safety warnings for erythropoiesis-stimulating agents.
Curtiss FR; Fairman KA
J Manag Care Pharm; 2009; 15(9):759-65. PubMed ID: 19954267
[No Abstract] [Full Text] [Related]
15. [Pharmacological and clinical profiles of long-lasting erythropoiesis-stimulating agent (darbepoetin alfa; NESP].
Nagano N
Nihon Yakurigaku Zasshi; 2008 Apr; 131(4):291-9. PubMed ID: 18408341
[No Abstract] [Full Text] [Related]
16. Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease.
Grabe DW
Am J Health Syst Pharm; 2007 Jul; 64(13 Suppl 8):S8-14; quiz S23-5. PubMed ID: 17591995
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
Mc Causland FR; Claggett B; Burdmann EA; Chertow GM; Cooper ME; Eckardt KU; Ivanovich P; Levey AS; Lewis EF; McGill JB; McMurray JJV; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto RD; Pfeffer MA
Am J Kidney Dis; 2019 Mar; 73(3):309-315. PubMed ID: 30578152
[TBL] [Abstract][Full Text] [Related]
18. Effect of darbepoetin alfa administered once monthly on maintaining hemoglobin levels in older patients with chronic kidney disease.
Silver MR; Agarwal A; Krause M; Lei L; Stehman-Breen C
Am J Geriatr Pharmacother; 2008 Jun; 6(2):49-60. PubMed ID: 18675764
[TBL] [Abstract][Full Text] [Related]
19. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
[TBL] [Abstract][Full Text] [Related]
20. Trick or TREAT? More condemning evidence against ESAs.
Zarowitz BJ
Geriatr Nurs; 2010; 31(1):52-4. PubMed ID: 20159353
[No Abstract] [Full Text] [Related]
[Next] [New Search]
